Drug Trial Radar · NCT03926117
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Jun 3, 2019
Primary completion
Jun 26, 2020
Study completion Jun 26, 2020
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 mg and 30 mg subcutaneous monthly compared to placebo for six months.
Conditions
- Chronic Kidney Diseases
- Inflammation
Interventions
ZiltivekimabBiological
human IgG1k anti-human IL-6 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) LevelsTime frame: Baseline (average of the hs-CRP value prior to randomization and day 1), week 13
Locations
49 sites in 1 country. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Aventiv Research
Mesa, Arizona
Arizona Kidney Disease and Hypertension Center
Phoenix, Arizona
Elite Clinical Studies
Phoenix, Arizona
North America Research Institute
Lynwood, California
North America Research Institute
Riverside, California
Apex Research of Riverside
Riverside, California
North America Research Institute
San Dimas, California
Western Nephrology and Metabolic Bone Disease, PC
Arvada, Colorado
AMPM Research Clinic
Miami, Florida
Ocala Cardiovascular Research
Ocala, Florida
Florida Premier Research Institue, LLC
Winter Park, Florida
Southeastern Clinical Research Institute, LLC
Augusta, Georgia
Columbus Regional Research Institute
Columbus, Georgia
Investigator Research by Design, LLC
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Clinical Trials of America, LLC - West Monroe
Monroe, Louisiana
Capital Nephrology
Greenbelt, Maryland
Onyx Clinical Research
Caro, Michigan
Henry Ford Health System
Detroit, Michigan
St. Clair Nephrology Research
Roseville, Michigan
Nephrology Research of Michigan
Saint Clair Shores, Michigan
DaVita Clinical Research
Minneapolis, Minnesota
Julia and Israel Waldbaum Dialysis Center
Great Neck, New York
Northport VAMC
Northport, New York
DaVita Clinical Research
The Bronx, New York
Mountain Kidney and Hypertension Associates
Asheville, North Carolina
Metrolina Nephrology Associates, PA
Charlotte, North Carolina
Metrolina Nephrology Associates
Charlotte, North Carolina
Southeastern Nephrology - Whiteville
Whiteville, North Carolina
Southeastern Nephrology Associates - Wilmington
Wilmington, North Carolina
Summit Research Group, LLC
Stow, Ohio
Northeast Clinical Research Center
Allentown, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Piedmont Research Partners, LLC
Fort Mill, South Carolina
Mountain View CLinical Research - Greer
Greer, South Carolina
Knoxville Kidney Center, PLLC
Knoxville, Tennessee
Nephrology Associates, PC
Nashville, Tennessee
Renal Disease Research Institute
Dallas, Texas
Vilo Research Group, Inc
Houston, Texas
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.